Document is current
Any future updates will be listed below
-
Authors
Bsteh, Gabriel
Macher, Stefan
Krajnc, Nik
Marik, Wolfgang
Michl, Martin
Müller, Nina
Zaic, Sina
Harreiter, Jürgen
Novak, Klaus
Wöber, Christian
Pemp, Berthold
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 25 July 2024
First Online: 1 August 2024
Declarations
:
: Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis. Stefan Macher: declares no conflict of interest relevant to this studyNik Krajnc: has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Wolfgang Marik: declares no conflict of interest relevant to this study.Martin Michl: declares no conflict of interest relevant to this study.Nina Müller: declares no conflict of interest relevant to this study.Sina Zaic: declares no conflict of interest relevant to this study.Jürgen Harreiter: declares no conflict of interest relevant to this study.Klaus Novak: declares no conflict of interest relevant to this study.Christian Wöber: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grünenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm/Teva, and Stada.Berthold Pemp: has received honoraria for consultancy/speaking from Chiesi, GenSight, Novartis and Santen.
